AbbVie | ABBV - Net Income

Stock Price
225.64
Daily Change
2.63 1.18%
Monthly
2.48%
Yearly
18.67%
Q1 Forecast
216.14

AbbVie reported $938M in Net Income for its fiscal quarter ending in June of 2025.





Net Income Change Date
AbbVie USD 938M 348M Jun/2025
Abbott USD 1.78B 132M Dec/2025
ALKERMES USD 82.76M 4.34M Sep/2025
Amgen USD 3.22B 1.78B Sep/2025
AstraZeneca USD 2.53B 83M Sep/2025
Biogen USD 466.5M 168.3M Sep/2025
BioMarin Pharmaceutical USD -30.74M 271.28M Sep/2025
Bristol-Myers Squibb USD 2.2B 891M Sep/2025
Eisai JPY 10.16B 4.32B Sep/2025
Eli Lilly USD 5.58B 78M Sep/2025
Gilead Sciences USD 3.05B 1.09B Sep/2025
GlaxoSmithKline GBP 2.01B 570M Sep/2025
J&J USD 5.12B 36M Dec/2025
Medtronic USD 1.37B 334M Sep/2025
Merck USD 5.78B 1.36B Sep/2025
Neurocrine Biosciences USD 209.5M 102M Sep/2025
Novartis USD 3.93B 96M Sep/2025
Pacira USD 5.43M 10.28M Sep/2025
Perrigo USD 7.5M 15.9M Sep/2025
Pfizer USD 3.54B 631M Sep/2025
Regeneron Pharmaceuticals USD 844.6M 615.4M Dec/2025
Roche Holding CHF 5.47B 1.76B Dec/2025
Sanofi EUR -801M 3.6B Dec/2025
UCB EUR 857M 649M Dec/2024
Ultragenyx Pharmaceutical USD -180.41M 65.46M Sep/2025
United Therapeutics USD 338.7M 29.2M Sep/2025
Vertex Pharmaceuticals USD 1.08B 50M Sep/2025
Zoetis USD 721M 3M Sep/2025